Key Takeaway
Review the key MOTS-c research studies, from its discovery to current clinical investigations on metabolism, aging, exercise performance, and insulin sensitivity.
· Peptide Q&A
MOTS-c research studies have demonstrated promising effects on metabolism, insulin sensitivity, exercise capacity, and aging. The peptide was first identified in 2015 by Dr. Changhan David Lee's lab at USC, and since then, both animal and early human studies have expanded our understanding of its potential.
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is encoded in the mitochondrial genome, making it one of a small group of peptides produced outside the nuclear DNA. This unique origin has driven significant scientific interest.
Foundational Discovery (2015)
The landmark study published in Cell Metabolism in 2015 identified MOTS-c as a signaling peptide derived from mitochondrial DNA. Researchers demonstrated that MOTS-c targets the folate-methionine cycle, which influences cellular metabolism and AMPK activation. In mouse models, MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance.
Exercise and Physical Performance
A 2020 study showed that MOTS-c levels naturally increase during exercise in humans, suggesting it acts as an exercise mimetic. Researchers found that endogenous MOTS-c production rises in skeletal muscle during physical exertion, and that administering MOTS-c to sedentary mice improved their exercise capacity.
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
This finding is notable because it positions MOTS-c not just as an external supplement but as part of the body's natural response to exercise. It raises the possibility that MOTS-c therapy could benefit individuals who can't exercise due to injury, illness, or mobility limitations.
Aging and Longevity
Research on MOTS-c and aging has revealed that circulating MOTS-c levels decline with age in both mice and humans. Studies from 2018 and 2019 showed that older adults have lower plasma MOTS-c concentrations compared to younger individuals.
From the FormBlends catalog
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →In aged mouse models, MOTS-c administration improved physical capacity, metabolic function, and certain markers associated with healthier aging. These results have fueled interest in MOTS-c as a potential geroprotective agent, though human longevity trials aren't yet underway.
Insulin Sensitivity and Metabolic Health
Multiple preclinical studies have confirmed that MOTS-c improves glucose uptake in skeletal muscle through AMPK-dependent pathways. In high-fat-diet mouse models, the peptide reduced weight gain, improved glucose tolerance, and lowered insulin resistance.
A small human pilot study showed that MOTS-c levels correlate inversely with body mass index and markers of metabolic syndrome, suggesting that lower levels may be associated with poorer metabolic health.
Limitations of Current Research
While the findings are promising, important caveats remain:
- Most studies have been conducted in mice. large-scale human clinical trials are limited.
- Optimal dosing, cycling, and long-term safety in humans haven't been established through controlled trials.
- Publication bias may skew toward positive results.
- The peptide's effects may vary significantly based on age, sex, and metabolic baseline.
Understanding peptide research stages
Frequently Asked Questions
Are there human clinical trials for MOTS-c?
Small pilot studies and observational studies have been conducted in humans, primarily measuring endogenous MOTS-c levels. Large-scale randomized controlled trials evaluating MOTS-c as a therapeutic intervention are still in early stages. Check ClinicalTrials.gov for the latest registered studies.
What is the most significant MOTS-c study to date?
The 2015 Cell Metabolism paper by Lee et al. is considered the foundational study. It identified the peptide, mapped its mechanism through the folate cycle and AMPK activation, and showed it prevented insulin resistance in mice. Subsequent studies have built on these findings.
Does MOTS-c research support its use for weight loss?
Animal studies show that MOTS-c can reduce fat accumulation and improve metabolic markers in obese mice. But no controlled human trial has confirmed weight-loss efficacy. Any weight-management claims based on current evidence should be considered preliminary.
Is MOTS-c research being conducted at major universities?
Yes. The primary research group is based at the University of Southern California under Dr. Changhan David Lee. Additional studies have been published by research teams in South Korea, China, and Japan, examining MOTS-c in various metabolic and aging contexts.
How can I stay updated on new MOTS-c studies?
Search PubMed for "MOTS-c" to find the latest peer-reviewed publications. You can also set up Google Scholar alerts for the term. ClinicalTrials.gov lists any registered human trials, giving visibility into upcoming research. how to read peptide research
Ready when you are
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →